Ultragenyx reported FY 2025 total revenues of USD 673 million (+20%), driven by higher demand for its approved products. Total product sales were USD 369 million (+29%), including Crysvita sales of USD 177 million (+31%), Dojolvi sales of USD 96 million (+9%), Evkeeza sales of USD 59 million (+84%), and Mepsevii sales of USD 37 million (+23%). Crysvita royalty revenue was USD 304 million (+11%), primarily due to an increase in the number of patients on therapy. The company posted a FY 2025 net loss of USD 575 million. Cost of sales was USD 109 million (+42%). Research and development expenses were USD 750 million (+7%), reflecting higher UX111 manufacturing costs in preparation for commercial launch and increased manufacturing and clinical activity for UX143 and GTX102; Ultragenyx said it expects R&D expenses to decrease in the near term due to expected completion of several Phase 3 programs and a strategic restructuring of its workforce and expenditures. Selling, general and administrative expenses were USD 349 million (+9%), mainly due to higher employee compensation and increased marketing as it plans for future launches. Ultragenyx ended FY 2025 with USD 737 million in available cash, cash equivalents and marketable securities, and said existing capital resources should fund projected operating requirements for at least the next 12 months. Cash used in operating activities was USD 466 million in FY 2025, while cash provided by financing activities was USD 478 million, including USD 392 million in net proceeds from the November 2025 sale of a percentage of future Crysvita royalties in the U.S. and Canada to OMERS and USD 80 million in net proceeds from its ATM program. Subsequent to Dec. 31, 2025, the company initiated a process to cancel certain CMO manufacturing arrangements for UX143 and expects terminations to accelerate net payments of approximately USD 40 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-057329), on February 18, 2026, and is solely responsible for the information contained therein.